Baricitinib restrains the immune dysregulation in patients with severe COVID-19.

Volume: 130, Issue: 12, Pages: 6409 - 6416
Published: Dec 1, 2020
Abstract
BACKGROUNDPatients with coronavirus disease 2019 (COVID-19) develop pneumonia generally associated with lymphopenia and a severe inflammatory response due to uncontrolled cytokine release. These mediators are transcriptionally regulated by the JAK/STAT signaling pathways, which can be disabled by small molecules.METHODSWe treated a group of patients (n = 20) with baricitinib according to an off-label use of the drug. The study was designed as an...
Paper Details
Title
Baricitinib restrains the immune dysregulation in patients with severe COVID-19.
Published Date
Dec 1, 2020
Volume
130
Issue
12
Pages
6409 - 6416
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.